NCT05621317View on ClinicalTrials.gov

A Safety and Efficacy Study of PVX108 in Children and Adolescents With Peanut Allergy

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

90

Participants

Timeline

Start Date

February 9, 2023

Primary Completion Date

November 30, 2025

Study Completion Date

June 30, 2027

Conditions
Peanut AllergyPeanut HypersensitivityPeanut-Induced AnaphylaxisImmune System Diseases
Interventions
BIOLOGICAL

PVX-108

PVX108 comprises a mixture of peptides that represent sequences from peanut allergens

BIOLOGICAL

Placebo

Matching placebo comprises the formulation vehicle without peptides

Trial Locations (14)

4101

Queensland Children's Hospital, South Brisbane

20815

IAA Clinical Research, Chevy Chase

21205

Johns Hopkins Hospital, Baltimore

27599

University of North Carolina at Chapel Hill, Chapel Hill

30329

Children's Healthcare of Atlanta, Atlanta

72202

Arkansas Children's Research Institute, Little Rock

90274

Peninsula Research Associates, Rolling Hills Estates

462020

Riley Children's Hospital at IU, Indianapolis

02114

Massachusetts General Hospital, Boston

Unknown

Sydney Children's Hospital, Randwick

The Children's Hospital at Westmead, Westmead

Women's and Children's Hospital, North Adelaide

The Royal Children's Hospital Melbourne, Parkville

Perth Children's Hospital, Nedlands

All Listed Sponsors
lead

Aravax Pty Ltd

INDUSTRY